Filter By Category
Archives
Share on -
AMLITELIMAB
Generic Name: AMLITELIMAB
ABSTRACT -
Amlitelimab is an investigational fully human monoclonal antibody that targets OX40 ligand (OX40L). By blocking OX40L-mediated T-cell co-stimulation without intentionally depleting T cells, it is being studied for immune-mediated inflammatory diseases, including atopic dermatitis. A standard small-molecule chemical structure is not applicable; the representation above is a biologic antibody schematic.
DOSAGE -
Dosage should be determined only by a qualified healthcare professional.
Amlitelimab dosing is investigational and should follow the clinical-trial or authorised access protocol.
Administration route and interval depend on the study design and disease being treated.
Clinical response and adverse events should be monitored by an immunology, dermatology, or respiratory specialist as applicable.
SIDE EFFECTS–
Possible side effects include:
- Nasopharyngitis
- Upper respiratory tract infection
- Headache
- Injection-site reaction
- Atopic dermatitis flare or skin irritation
- Fever or fatigue
- Nausea
- Possible immunogenicity or anti-drug antibodies
- Serious infection or hypersensitivity is possible but not fully characterised.
ALLRGIC REACTIONS–
- Hypersensitivity to amlitelimab or excipients may occur.
- Symptoms may include rash, urticaria, angioedema, wheezing, hypotension, fever, or anaphylaxis.
- Important: Patients with allergic symptoms after Amlitelimab should seek urgent medical attention.
DRUG INTERACTIONS–
- CYP enzyme interactions are not expected for monoclonal antibodies.
- Use caution with other biologics, systemic immunosuppressants, or investigational immune therapies.
- Live vaccines should generally be avoided or timed according to specialist guidance.
- Patients should inform healthcare providers about all medicines and supplements.
PREAUTIONS–
- Screen for clinically significant infection before starting therapy.
- Monitor for infections, hypersensitivity, and worsening inflammatory disease.
- Safety in pregnancy, lactation, severe organ impairment, and paediatric use is not fully established.
- Do not use outside authorised clinical or specialist settings.
WARNINGS –
- Amlitelimab is investigational and not approved for general unsupervised use.
- Serious hypersensitivity and infection are potential risks of immune-modulating biologics.
- Treatment should be stopped and assessed if severe infection or anaphylaxis occurs.
- Keep out of reach of children.
Share on -
. Developed by